Sorafenib promotes the differentiation of skin squamous cell carcinoma SCC by inhibiting the B-Raf/Mek/Erk pathway, and inhibits the growth of its tumor tissue (Cheepala et al. 2009). Here, MAP2K7 is linked to skin squamous cell carcinoma.